Back to results
US 2019/0168943 A1Published application
Packaging system for oxygen-sensitive drugs
AssigneeFresenius Kabi Deutschland GmbH
InventorsThomas DEVOUASSOUX, Eric FORAT, James Kenneth PROCTOR
Life of this patent
Estimating the term…
Abstract
Described herein are pharmaceutical packaging systems which prevent oxidative degradation of oxygen-sensitive drugs, such systems including a primary packaging container with an oxygen permeable component, a secondary packaging with very low permeability to oxygen and an oxygen absorber.
Claims22
A pharmaceutical product comprising:
- (i) a container filled under inert conditions with an injectable oxygen-sensitive drug, wherein the container has an oxygen permeable component,
- (ii) a hermetically sealed oxygen barrier blister packaging which houses the container, wherein the blister packaging comprises a multilayer bottom web and a multilayer top web lid each comprised of an oxygen barrier material;
- and
- (iii) an oxygen absorber inside the blister packaging, wherein the oxygen absorber reduces the oxygen level present from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the container, and the oxygen levels in the blister packaging and in the container remain at about zero percent for at least one year after the initial reduction in oxygen levels.
1 more element
A pharmaceutical product comprising:
- (i) a container filled under inert conditions with morphine, wherein the container has an oxygen permeable component,
- (ii) a hermetically sealed oxygen barrier blister packaging which houses the container, wherein the blister packaging comprises a multilayer bottom web and a multilayer top web lid each comprised of an oxygen barrier material;
- and
- (iii) an oxygen absorber inside the blister packaging, wherein the oxygen absorber reduces the oxygen level present from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the container, and the oxygen levels in the blister packaging and in the container remain at about zero percent for at least one year after the initial reduction in oxygen levels.
1 more element
A pharmaceutical product comprising:
- (i) a container filled under inert conditions with hydromorphone, wherein the container has an oxygen permeable component,
- (ii) a hermetically sealed oxygen barrier blister packaging which houses the container, wherein the blister packaging comprises a multilayer bottom web and a multilayer top web lid each comprised of an oxygen barrier material;
- and
- (iii) an oxygen absorber inside the blister packaging, wherein the oxygen absorber reduces the oxygen level present from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the container, and the oxygen levels in the blister packaging and in the container remain at about zero percent for at least one year after the initial reduction in oxygen levels.
1 more element
Dependencies are inferred from the claim text.